The conversation is about hair loss treatments, including dermarolling, Minoxidil, Finasteride, and RU58841. Users discuss their experiences, side effects, and application methods for these treatments.
User shared 2-year progress with Dutasteride, 5mg oral minoxidil, and 7 months of RU58841 for hair growth. RU58841 was most effective, stopping itching and promoting significant growth.
The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
A user is starting treatment for hair loss with topical minoxidil, oral finasteride, and is considering adding topical latanoprost but is unsure about the application frequency and method for latanoprost. They are seeking advice from others with experience using these treatments.
Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.
The conversation is about a 23-year-old who started treating their hair loss with daily oral dutasteride (0.5mg), oral minoxidil (2.5mg), topical RU58841 (80mg), and weekly microneedling at 1.5mm after seeing others' success stories. Significant improvements have been noted, and there is optimism for even better results in the next 6 months.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.
Broccoli or sulforaphane supplements are unlikely to improve Minoxidil results due to the need for an unrealistically large dose. Tretinoin, micro-needling, and low-dose oral Minoxidil may be more effective for those lacking the necessary enzyme in the scalp.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
RU58841 for hair loss, discussing sources, application methods, and carriers like PG + ethanol or liquid minoxidil. Users share experiences with premixed solutions and powder forms, noting price differences and storage importance.
Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.
Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.
Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.
The user has been using finasteride for a year to stop hair loss and is considering adding RU58841 instead of minoxidil to further inhibit DHT. Another user suggests adding dutasteride for better DHT inhibition, but the original user cannot access it and is considering RU58841 despite potential side effects.
A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.
People discuss adding RU58841 to their hair loss treatment, which includes dutasteride and minoxidil. Experiences vary, with some reporting positive results and others experiencing no benefits or side effects.
The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.
A 21-year-old is using Dualgen-5R (minoxidil and tretinoin) and weekly dermarolling to address hair loss, noticing some progress after three months. They plan to add an anti-androgen like RU58841 or Kx826 for better long-term results.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
The conversation discusses the safety and effectiveness of continuing or adding RU58841 after stopping finasteride for hair loss treatment. One user expresses skepticism about using RU58841 due to the lack of full human trials.
RU58841 powder is mixed with a 70% ethanol and 30% propylene glycol solution, with some users seeking PG-free alternatives. Minoxidil is also mentioned as a treatment option.
The conversation discusses using topical dutasteride from minoxidilmax for hair loss and the possibility of crowdfunding for DHT blood tests to check if the treatment goes systemic. The user plans to post before and after pictures.
An 18-year-old has been using minoxidil and finasteride for hair loss since age 15, recently adding dutasteride and GHK-Cu, but sees no significant improvement and is considering a hair transplant. Concerns are raised about using hormone suppressors at a young age, with suggestions to explore other treatments like dermarolling, diet changes, and checking for deficiencies.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.